| Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling SM Pitson, P Xia, TM Leclercq, PAB Moretti, JR Zebol, HE Lynn, ... The Journal of experimental medicine 201 (1), 49-54, 2005 | 334 | 2005 |
| The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells C Loveridge, F Tonelli, T Leclercq, KG Lim, JS Long, E Berdyshev, ... Journal of Biological Chemistry 285 (50), 38841-38852, 2010 | 142 | 2010 |
| Cellular signalling by sphingosine kinase and sphingosine 1‐phosphate TM Leclercq, SM Pitson IUBMB life 58 (8), 467-472, 2006 | 75 | 2006 |
| An oncogenic role for sphingosine kinase 2 HA Neubauer, DH Pham, JR Zebol, PAB Moretti, AL Peterson, ... Oncotarget 7 (40), 64886, 2016 | 65 | 2016 |
| Eukaryotic elongation factor 1A interacts with sphingosine kinase and directly enhances its catalytic activity TM Leclercq, PAB Moretti, MA Vadas, SM Pitson Journal of biological chemistry 283 (15), 9606-9614, 2008 | 65 | 2008 |
| Guanine nucleotides regulate sphingosine kinase 1 activation by eukaryotic elongation factor 1A and provide a mechanism for eEF1A-associated oncogenesis TM Leclercq, PAB Moretti, SM Pitson Oncogene 30 (3), 372-378, 2011 | 58 | 2011 |
| Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: functional differences between sphingosine kinase 1a and 1b KG Lim, F Tonelli, E Berdyshev, I Gorshkova, T Leclercq, SM Pitson, ... The international journal of biochemistry & cell biology 44 (9), 1457-1464, 2012 | 52 | 2012 |
| Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia L Schafranek, E Nievergall, JA Powell, DK Hiwase, T Leclercq, ... Leukemia 29 (1), 76-85, 2015 | 49 | 2015 |
| Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy L Schafranek, TM Leclercq, DL White, TP Hughes Leukemia & lymphoma 54 (1), 198-201, 2013 | 42 | 2013 |
| Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells L Lu, VA Saunders, TM Leclercq, TP Hughes, DL White Leukemia 29 (8), 1792-1794, 2015 | 30 | 2015 |
| Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib CH Kok, DT Yeung, L Lu, DB Watkins, TM Leclercq, P Dang, VA Saunders, ... Blood advances 3 (10), 1610-1621, 2019 | 29 | 2019 |
| Low GFI1 expression in white blood cells of CP–CML patients at diagnosis is strongly associated with subsequent blastic transformation CH Kok, DB Watkins, T Leclercq, RJ D'andrea, TP Hughes, DL White Leukemia 27 (6), 1427-1430, 2013 | 16 | 2013 |
| Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells J Wang, L Lu, CH Kok, VA Saunders, JM Goyne, P Dang, TM Leclercq, ... haematologica 102 (5), 843, 2017 | 13 | 2017 |
| Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients CH Kok, T Leclercq, DB Watkins, V Saunders, J Wang, TP Hughes, ... Leukemia 28 (3), 702-705, 2014 | 10 | 2014 |
| Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia DM Ross, IS Pagani, YD Irani, J Clarson, T Leclercq, P Dang, J McLean, ... British Journal of Haematology 186 (3), e56-e60, 2019 | 9 | 2019 |
| Modelling predictors of molecular response to frontline Imatinib for patients with chronic myeloid Leukaemia H Banjar, D Ranasinghe, F Brown, D Adelson, T Kroger, T Leclercq, ... PloS one 12 (1), e0168947, 2017 | 6 | 2017 |
| A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib CH Kok, TM Leclercq, D Watkins, DT Yeung, VA Saunders, DL White, ... Blood 126 (23), 596, 2015 | 5 | 2015 |
| The allosteric inhibitor ABL001 is susceptible to resistance in vitro mediated by overexpression of the drug efflux transporters ABCB1 and ABCG2 LN Eadie, VA Saunders, TM Leclercq, S Branford, DL White, TP Hughes Blood 126 (23), 4841, 2015 | 4 | 2015 |
| In vitro modeling of Ph-like ALL fusions identifies novel kinase-domain mutations as mode of TKI-resistance-implications for targeted therapy K Asari, SL Heatley, T Sadras, TM Leclercq, S Fitter, CH Kok, ... Blood 128 (22), 3957, 2016 | 3 | 2016 |
| Modeling ponatinib resistance in BCR-ABL1+ cell lines: implications for Ponatinib resistance in TKI-resistant and TKI-naïve patients L Lu, V Saunders, CH Kok, T Leclercq, TP Hughes, DL White Blood 124 (21), 4515, 2014 | 3 | 2014 |
